title: Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery.
abstract: The pharmacokinetics of propranolol may be altered by hypothermic cardiopulmonary bypass (CPB), resulting in unpredictable postoperative hemodynamic responses to usual doses. The objective of the present study was to investigate the pharmacokinetics of propranolol in patients undergoing coronary artery bypass grafting (CABG) by CPB under moderate hypothermia. We evaluated 11 patients, 4 women and 7 men (mean age 57 +/- 8 years, mean weight 75.4 +/- 11.9 kg and mean body surface area 1.83 +/- 0.19 m(2)), receiving propranolol before surgery (80-240 mg a day) and postoperatively (10 mg a day). Plasma propranolol levels were measured before and after CPB by high-performance liquid chromatography. Pharmacokinetic Solutions 2.0 software was used to estimate the pharmacokinetic parameters after administration of the drug pre- and postoperatively. There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery. In conclusion, increases in drug distribution could be explained in part by hemodilution during CPB. On the other hand, the increase of biological half-life can be attributed to changes in hepatic metabolism induced by CPB under moderate hypothermia. These alterations in the pharmacokinetics of propranolol after CABG with hypothermic CPB might induce a greater myocardial depression in response to propranolol than would be expected with an equivalent dose during the postoperative period.
authors.affiliation: Disciplina de Anestesiologia, Serviço de Anestesiologia e Terapia Intensiva Cirúrgica, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São PauloSão Paulo, SP, Brasil. maria.carmona@incor.usp.br
authors.forename: M J C
authors.initials: MJ
authors.lastname: Carmona
authors.forename: L M S
authors.initials: LM
authors.lastname: Malbouisson
authors.forename: V A
authors.initials: VA
authors.lastname: Pereira
authors.forename: M A
authors.initials: MA
authors.lastname: Bertoline
authors.forename: C E K
authors.initials: CE
authors.lastname: Omosako
authors.forename: K B
authors.initials: KB
authors.lastname: Le Bihan
authors.forename: J O C
authors.initials: JO
authors.lastname: Auler
authors.forename: S R C J
authors.initials: SR
authors.lastname: Santos
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000097:blood / Q000493:pharmacokinetics*; D000328:Adult; D000368:Aged; D002315:Cardiopulmonary Bypass; D002851:Chromatography, High Pressure Liquid; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood* / Q000601:surgery; D005260:Female; D006801:Humans; D007036:Hypothermia, Induced; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011433:Propranolol / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol